Dyno Therapeutics to Present on Breakthroughs in AI Methods for AAV Capsid Design at ASGCT Annual Congress and SynBioBeta Global Synthetic Biology Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that can expand the potential of genetic medicine, today announced the launch of its Dyno bCap 1™ capsid product, a breakthrough CNS-targeted AAV gene delivery vector with best-in-class potential, in a keynote address at the company’s Scientific Symposium at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting. The Dyno bCap 1 vector provides dramatically improved CNS delivery and liver detargeting compared to leading natural capsids and stronger all-around characteristics relative to other engineered CNS-IV capsids.
WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineering AAV capsids that can expand the potential of genetic medicine, today announced a Dyno Scientific Symposium and the presentation of four research abstracts at the upcoming 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 16-20, 2023 in Los Angeles, Calif.
Novo Nordisk, Sanofi and Eli Lilly offered big discounts for their insulin products in China. Astellas partnered with Dyno Therapeutics on viral vectors for gene therapy. Fujifilm is pouring $530 million into its U.K. facility. And more.
On the hunt for a better AAV capsid for gene therapy, Eric Kelsic’s Dyno Therapeutics has set itself apart with its focus on machine learning to help speed discovery. Now, Japanese drugmaker Astellas — fresh off a slate of gene therapy burns — is taking a bet on Dyno as it looks to the future.
Astellas is dishing out $18 million upfront and up to $1.6 billion in milestone and royalty payments to develop adeno-associated virus (AAV) vectors for gene therapies. The research tie-up follows a deal between Dyno and Roche and its Spark Therapeutics unit, which was disclosed last October and could balloon to above $1.8 billion.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, a biotechnology company applying artificial intelligence (AI) to gene therapy, will describe ongoing enhancements to its machine learning platform in three oral presentations at the 24th annual meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place virtually from May 11-14, 2021.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced a $100 million Series A financing led by Andreessen Horowitz, with participation from a select syndicate of new investors including Casdin Capital, GV, Obvious Ventures and Lux Capital. Founding investors Polaris Partners, CRV and KdT Ventures all participated in the round. Funds from this financing will directly fund expansion of the company’s CapsidMap™ platform, which uses AI technology for the design of novel Adeno-Associated Virus (AAV) gene therapy vectors, broadening the functionality and enhancing the therapeutic impact of gene therapies developed by Dyno’s biopharmaceutical partners.
Dyno Therapeutics, a Cambridge biotech that uses artificial intelligence techniques to develop gene therapies, said Thursday that it has raised $100 million from investors.
Adeno-associated viruses (AAV) for gene therapy have received a ton of scrutiny throughout the field’s history after a smattering of safety scares and their limited therapeutic range. Hoping to crack the field wide open through a capsid design revolution, Eric Kelsic and his team at Dyno have drummed up immense excitement — and now a hefty war chest.